Fantastic reading, as expected.
I have confidence in their approach below - which history show is exactly what they did for PhII for Trof - and we all know how that turned out
"In order to accelerate the overall development plan, in parallel with conducting the Phase 2 trials Neuren is executing the additional development work
required to be ready for Phase 3 development. This includes non-clinical toxicity studies to support longer clinical trials and commercial use of the product as well as optimisation of the drug product and drug substance manufacturing arrangements."
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.41 |
Change
-0.130(1.04%) |
Mkt cap ! $1.559B | |||
| Open | High | Low | Value | Volume |
| $12.61 | $12.68 | $12.34 | $151.7K | 12.19K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 156 | $12.38 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.41 | 49 | 3 |
View Market Depth
| Last trade - 10.07am 25/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |